PE20130184A1 - Compuesto heterociclico - Google Patents

Compuesto heterociclico

Info

Publication number
PE20130184A1
PE20130184A1 PE2012001253A PE2012001253A PE20130184A1 PE 20130184 A1 PE20130184 A1 PE 20130184A1 PE 2012001253 A PE2012001253 A PE 2012001253A PE 2012001253 A PE2012001253 A PE 2012001253A PE 20130184 A1 PE20130184 A1 PE 20130184A1
Authority
PE
Peru
Prior art keywords
methyl
pyrimidin
pyrazole
compounds
optionally substituted
Prior art date
Application number
PE2012001253A
Other languages
English (en)
Inventor
Misaki Homma
Toru Miyazaki
Yuya Oguro
Osamu Kurasawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44482985&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20130184(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20130184A1 publication Critical patent/PE20130184A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/20—Spiro-condensed systems

Abstract

SE REFIERE A COMPUESTOS HETEROCICLICOS FUSIONADOS DE FORMULA (I) DONDE: R1 ES ALQUILO C1-6 OPCIONALMENTE SUSTITUIDO CON HALOGENO; R2 ES UN GRUPO HIDROCARBONADO, GRUPO HETEROCICLICO O GRUPO HETEROCICLIL-CARBONILO NO AROMATICO OPCIONALMENTE SUSTITUIDOS; X ES S; Y ES CH O UNA DE SUS SALES. SON COMPUESTOS PREFERIDOS: 2-(2-CLOROFENIL)-6-(5-METIL-1H-PIRAZOL-4-IL)TIENO[3,2-d]PIRIMIDIN-4(3H)-ONA, 2-{[(3S)-3-FLUOROPIRROLIDIN-1-IL]METIL}-6-(5-METIL-1H-PIRAZOL-4-IL)TIENO[3,2-d]PIRIMIDIN-4(3H)-ONA, ENTRE OTROS. DICHOS COMPUESTOS TIENEN UNA ACTIVIDAD INHIBIDORA DEL CICLO DE DIVISION CELULAR 7 (Cdc7) SIENDO UTIL PARA LA PREVENCION O EL TRATAMIENTO DE CANCER
PE2012001253A 2010-02-17 2011-02-16 Compuesto heterociclico PE20130184A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2010031899 2010-02-17
JP2010131950 2010-06-09

Publications (1)

Publication Number Publication Date
PE20130184A1 true PE20130184A1 (es) 2013-03-09

Family

ID=44482985

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2012001253A PE20130184A1 (es) 2010-02-17 2011-02-16 Compuesto heterociclico

Country Status (35)

Country Link
US (6) US8722660B2 (es)
EP (2) EP3533797B1 (es)
JP (1) JP5689454B2 (es)
KR (1) KR101735868B1 (es)
CN (1) CN102844320B (es)
AU (1) AU2011216404B2 (es)
BR (1) BR112012020311B1 (es)
CA (1) CA2790284C (es)
CL (1) CL2012002250A1 (es)
CO (1) CO6592104A2 (es)
CR (1) CR20120448A (es)
CY (1) CY1121792T1 (es)
DK (1) DK2540728T3 (es)
DO (1) DOP2012000224A (es)
EA (1) EA020724B1 (es)
EC (1) ECSP12012160A (es)
ES (1) ES2733221T3 (es)
GE (1) GEP20146202B (es)
HR (1) HRP20190947T1 (es)
HU (1) HUE043514T2 (es)
IL (1) IL221442A0 (es)
LT (1) LT2540728T (es)
MA (1) MA34064B1 (es)
ME (1) ME03410B (es)
MX (1) MX353500B (es)
MY (1) MY164776A (es)
NZ (1) NZ602089A (es)
PE (1) PE20130184A1 (es)
PL (1) PL2540728T3 (es)
PT (1) PT2540728T (es)
RS (1) RS58796B1 (es)
SG (1) SG183304A1 (es)
SI (1) SI2540728T1 (es)
TN (1) TN2012000401A1 (es)
WO (1) WO2011102399A1 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA34797B1 (fr) * 2010-08-11 2014-01-02 Millennium Pharm Inc Hétéroaryles et leurs utilisations
EP3100742B1 (en) 2014-01-31 2020-05-20 Carna Biosciences Inc. Anticancer agent composition comprising a cdc7 inhibitor and a wee1 inhibitor
TW201620879A (zh) 2014-04-28 2016-06-16 杜邦股份有限公司 除草性經取代之３－苯基－４－氟基苯甲醯基吡唑
US10174032B2 (en) * 2014-05-05 2019-01-08 Signalrx Pharmaceuticals, Inc. Heterocyclic compound classes for signaling modulation
KR20190090081A (ko) 2015-12-07 2019-07-31 지머젠 인코포레이티드 Htp 게놈 공학 플랫폼에 의한 미생물 균주 개량
SG11201804901WA (en) 2015-12-22 2018-07-30 SHY Therapeutics LLC Compounds for the treatment of cancer and inflammatory disease
WO2017172565A1 (en) 2016-03-28 2017-10-05 Takeda Pharmaceutical Company Limited Crystalline forms of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6-(3-methyl-1h- pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one hemihydrate
EA035560B1 (ru) * 2016-07-28 2020-07-07 Такеда Фармасьютикал Компани Лимитед Кристаллические формы гемигидрата 2-[(2s)-1-азабицикло[2.2.2]окт-2-ил]-6-(3-метил-1h-пиразол-4-ил)тиено[3,2- d]пиримидин-4(3h)-она
AU2017359561B2 (en) 2016-11-08 2022-02-03 Cancer Research Technology Limited Pyrimidinone derivatives as Cdc7 inhibitors
WO2018158898A1 (en) 2017-03-01 2018-09-07 Takeda Pharmaceutical Company Limited Method of predicting effects of cdc7 inhibitor
WO2018217439A1 (en) * 2017-05-21 2018-11-29 Zhang Hai Jun Substituted [5,6]cyclic-4(3h)-pyrimidinones as anticancer agents
EA201992780A1 (ru) 2017-06-21 2020-06-02 ШАЙ ТЕРАПЬЮТИКС ЭлЭлСи Соединения, которые взаимодействуют с суперсемейством ras, для лечения рака, воспалительных заболеваний, ras-опатий и фиброзного заболевания
WO2019194319A1 (en) 2018-04-02 2019-10-10 Takeda Pharmaceutical Company Limited Process for the synthesis of 2-[(2s)-1-azabicyclo[2.2.2]oct-2-yl]-6- (3-methyl-1 h-pyrazol-4-yl)thieno[3,2-d]pyrimidin-4(3h)-one
TW202016316A (zh) 2018-06-19 2020-05-01 日商武田藥品工業股份有限公司 癌症治療方法
US20210308061A1 (en) 2018-07-19 2021-10-07 Taked Pharmaceutical Company Limited Pharmaceutical compositions with a cdc7 inhibitor
CA3142202A1 (en) * 2019-05-30 2020-12-03 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Tetracyclic compounds as cdc7 inhibitors
WO2021015294A2 (en) 2019-07-19 2021-01-28 Takeda Pharmaceutical Company Limited Combination therapy for cancer treatment
WO2021032170A1 (zh) * 2019-08-20 2021-02-25 南京明德新药研发有限公司 用作Cdc7抑制剂的四并环类化合物
EP4069369A4 (en) * 2019-12-06 2024-02-14 Schroedinger Inc CYCLIC COMPOUNDS AND METHODS OF USE THEREOF
WO2022055963A1 (en) * 2020-09-10 2022-03-17 Schrödinger, Inc. Heterocyclic pericondensed cdc7 kinase inhibitors for the treatment of cancer
CN116472046A (zh) * 2020-11-30 2023-07-21 正大天晴药业集团股份有限公司 作为Cdc7抑制剂的盐型及其晶型
CN112661770B (zh) * 2020-12-24 2022-11-08 南京正济医药研究有限公司 一种化合物及利用其制备取代的[5,6]环-4(3h)-嘧啶酮化合物的方法
WO2022167999A1 (en) 2021-02-08 2022-08-11 Takeda Pharmaceutical Company Limited Combination therapy for cancer treatment
TW202300150A (zh) * 2021-03-18 2023-01-01 美商薛定諤公司 環狀化合物及其使用方法
TW202330552A (zh) * 2021-10-13 2023-08-01 美商雷密克斯醫療公司 調節剪接之化合物及方法

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196207A (en) * 1977-05-23 1980-04-01 Ici Australia Limited Process for controlling eradicating or preventing infestations of animals by Ixodid ticks
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
AU2001290311A1 (en) 2000-09-29 2002-04-08 Nippon Soda Co., Ltd. Thienopyrimidine compounds and their salts and process for preparation of both
US6503914B1 (en) 2000-10-23 2003-01-07 Board Of Regents, The University Of Texas System Thienopyrimidine-based inhibitors of the Src family
US20030096813A1 (en) 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
AU2003246972A1 (en) 2002-08-06 2004-02-23 Astrazeneca Ab Condensed pyridines and pyrimidines with tie2 (tek) activity
WO2004111014A1 (en) 2003-06-06 2004-12-23 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as modulators of atp-binding cassette transporters
MXPA05013549A (es) * 2003-06-11 2006-04-05 Xention Discovery Ltd Derivados de tienopirimidina como inhibidores del canal de potasio.
US20050032869A1 (en) 2003-07-08 2005-02-10 Pharmacia Italia S.P.A. Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
BRPI0413438A (pt) * 2003-08-08 2006-10-17 Pharmacia Italia Spa derivados de pirimidilpirrol ativos como inibidores de cinase
US7279575B2 (en) 2003-08-08 2007-10-09 Pfizer Italia S.R.L. Pyrimidylpyrrole derivatives active as kinase inhibitors
BRPI0508230A (pt) * 2004-03-30 2007-07-17 Chiron Corp derivados de tiofeno substituìdo como agentes anti-cáncer
EP1757306A4 (en) 2004-04-09 2010-05-19 Genecare Res Inst Co Ltd AGENT INDUCING APOPTOSIS SPECIFIC TO CARCINOMA CELLS TARGETING A GENE INVOLVED IN STABILIZING CHROMOSOMES
US20080102068A1 (en) 2005-01-19 2008-05-01 Coleman Paul J Mitotic Kinesin Inhibitors
WO2007011284A1 (en) 2005-07-15 2007-01-25 Astrazeneca Ab Therapeutic agents
CN101253166B (zh) 2005-08-30 2013-07-10 旭化成制药株式会社 磺酰胺化合物
FI20055498A0 (fi) 2005-09-16 2005-09-16 Biotie Therapies Corp Sulfonamidijohdannaisia
US20070142414A1 (en) * 2005-12-16 2007-06-21 Pharmacia Italia S.P.A. N-substituted pyrrolopyridinones active as kinase inhibitors
US7618982B2 (en) * 2005-12-19 2009-11-17 Nerviano Medical Sciences S.R.L. Heteroarylpyrrolopyridinones active as kinase inhibitors
KR100846988B1 (ko) 2006-03-06 2008-07-16 제일약품주식회사 신규한 티에노피리미딘 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 함유하는 약학조성물
US20090030196A1 (en) 2006-12-29 2009-01-29 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
TW200836743A (en) 2007-01-29 2008-09-16 Xenon Pharmaceuticals Inc Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
WO2009001214A2 (en) 2007-06-28 2008-12-31 Pfizer Products Inc. Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
US20090118276A1 (en) 2007-11-02 2009-05-07 Wyeth Thienopyrimidines, thienopyridines, and pyrrolopyrimidines as b-raf inhibitors
US20110098288A1 (en) 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
AU2009262022A1 (en) 2008-06-26 2009-12-30 Dana-Farber Cancer Institute, Inc. Signatures and determinants associated with metastasis and methods of use thereof
US8691828B2 (en) 2009-03-05 2014-04-08 Takeda Pharmaceutical Company Limited Thienopyrimidine as CDC7 kinase inhibitors
WO2010126002A1 (ja) 2009-04-28 2010-11-04 塩野義製薬株式会社 ヘテロ環スルホンアミド化合物を含有する医薬
TW201111378A (en) 2009-09-11 2011-04-01 Bayer Schering Pharma Ag Substituted (heteroarylmethyl) thiohydantoins
CA2773615A1 (en) 2009-09-11 2011-03-17 Arwed Cleve Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
AR079343A1 (es) 2009-12-21 2012-01-18 Lilly Co Eli Compuesto de acido 2-amino-4-(4h-1,2,4-triazol-3-ilsulfanil)biciclo[3.1.0]hexano-2,6-dicarboxilico, composicion farmaceutica que lo comprende y su uso para preparar un medicamento util para tratar un trastorno psiquiatrico

Also Published As

Publication number Publication date
TN2012000401A1 (en) 2014-01-30
PT2540728T (pt) 2019-07-11
CA2790284C (en) 2019-01-08
US20170209452A1 (en) 2017-07-27
ECSP12012160A (es) 2013-03-28
DOP2012000224A (es) 2013-01-31
BR112012020311B1 (pt) 2019-01-29
US9655900B2 (en) 2017-05-23
US20160310494A1 (en) 2016-10-27
SG183304A1 (en) 2012-09-27
US20140235615A1 (en) 2014-08-21
EP3533797B1 (en) 2023-12-20
JP5689454B2 (ja) 2015-03-25
MX2012009602A (es) 2012-12-17
US20150158882A1 (en) 2015-06-11
AU2011216404B2 (en) 2016-04-07
HUE043514T2 (hu) 2019-08-28
US8933069B2 (en) 2015-01-13
RS58796B1 (sr) 2019-07-31
BR112012020311A2 (pt) 2017-03-01
SI2540728T1 (sl) 2019-06-28
MY164776A (en) 2018-01-30
EP2540728A1 (en) 2013-01-02
CR20120448A (es) 2012-11-13
CY1121792T1 (el) 2020-07-31
PL2540728T3 (pl) 2019-09-30
US20130029969A1 (en) 2013-01-31
HRP20190947T1 (hr) 2019-07-26
KR101735868B1 (ko) 2017-05-15
CN102844320A (zh) 2012-12-26
IL221442A0 (en) 2012-10-31
MA34064B1 (fr) 2013-03-05
MX353500B (es) 2018-01-16
CA2790284A1 (en) 2011-08-25
WO2011102399A1 (ja) 2011-08-25
EP2540728A4 (en) 2013-11-06
GEP20146202B (en) 2014-11-25
EA020724B1 (ru) 2015-01-30
DK2540728T3 (da) 2019-05-13
CL2012002250A1 (es) 2013-02-08
AU2011216404A1 (en) 2012-09-20
JPWO2011102399A1 (ja) 2013-06-17
CO6592104A2 (es) 2013-01-02
EP3533797A1 (en) 2019-09-04
ES2733221T3 (es) 2019-11-28
EA201290800A1 (ru) 2013-03-29
LT2540728T (lt) 2019-06-25
KR20130001246A (ko) 2013-01-03
EP2540728B1 (en) 2019-04-10
ME03410B (me) 2020-01-20
US8722660B2 (en) 2014-05-13
US9388195B2 (en) 2016-07-12
CN102844320B (zh) 2016-03-23
US8921354B2 (en) 2014-12-30
NZ602089A (en) 2014-05-30
US20140228352A1 (en) 2014-08-14

Similar Documents

Publication Publication Date Title
PE20130184A1 (es) Compuesto heterociclico
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PE20141974A1 (es) Compuestos de heterociclilo
PE20191142A1 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
PE20170677A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
PE20141361A1 (es) Compuesto heterociclico dihidroxi aromatico
PE20142019A1 (es) Nuevos derivados de acidos indaniloxidihidrobenzofuranilaceticos y sus usos como agonistas del receptor gpr40
PE20171057A1 (es) Derivados espirodiamina como inhibidores de la aldosterona sintasa
PE20150230A1 (es) Nuevos diazaespirocicloalcanos y azaespirocicloalcanos
PE20200447A1 (es) Compuestos de biheteroarilo y usos de los mismos
PE20130457A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
PE20140245A1 (es) Compuesto de furo[3,2-d]pirimidina
PE20141203A1 (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
PE20140927A1 (es) Compuestos heterociclicos como inhibidores de cinasas
PE20140192A1 (es) Derivados de bencimidazol como inhibidores de cinasa pi3
PE20151538A1 (es) Nuevos compuestos como inhibidores de reorganizado durante la transfeccion (ret)
CY1112151T1 (el) Αγωνιστες τυπου πυριδονης του συζευγμενου με g-πρωτεϊνη υποδοχεα gpr119
PE20141828A1 (es) 6-alquinilo piridinas como mimeticos smac
AR080688A1 (es) Derivados de 2,3-dihidro-1h-inden-1-il-2,7-diazaspiro[3.5]nonano como agonistas o antagonistas inversos de grelina
UY34219A (es) Compuestos de 2-(2,4,5-anilino sustituido)pirimidina
PE20110419A1 (es) Compuestos de pirrolo-pirimidina como inhibidores de cdk
PE20170331A1 (es) Derivados quinolina como inhibidores smo
PE20160664A1 (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
PE20141823A1 (es) Derivados de tetrahidro-quinazolinona
DOP2013000027A (es) Derivados de tetrahidro-pirido-pirimidina

Legal Events

Date Code Title Description
FG Grant, registration